Description
Onco BCG 40 mg – Advanced Immunotherapy for Bladder Cancer
Onco BCG 40 mg is a specialized immunotherapy medication used in the treatment and prevention of recurrence of non-muscle invasive bladder cancer (NMIBC). It contains a live attenuated strain of Bacillus Calmette-Guérin (BCG) that stimulates the body’s immune system to attack cancer cells in the bladder. By activating local immune responses, Onco BCG helps destroy tumor cells and reduces the risk of cancer recurrence after tumor removal procedures.
📋 Product Profile
Active Component: Bacillus Calmette-Guérin (BCG) – Live attenuated strain
Strength: 40 mg
Therapeutic Class: Immunotherapy / Antineoplastic Agent
Target: Non-Muscle Invasive Bladder Cancer (NMIBC)
Dosage Form: Intravesical Suspension for Bladder Instillation
🎯 Primary Indications
Onco BCG 40 mg is commonly prescribed for the management of:
Non-Muscle Invasive Bladder Cancer (NMIBC):
Used after tumor removal surgery (TURBT) to destroy remaining cancer cells.
Carcinoma in Situ (CIS) of the Bladder:
Effective in treating flat high-grade cancer cells confined to the bladder lining.
Prevention of Cancer Recurrence:
Reduces the chances of bladder tumor recurrence and progression.
Adjunct Therapy Post-Surgery:
Administered following transurethral resection of bladder tumor (TURBT) to enhance immune-mediated tumor destruction.
⚙️ Mechanism of Action
Onco BCG works through immune system activation within the bladder:
Immune Stimulation:
The BCG bacteria activate the body’s immune response in the bladder lining.
Inflammatory Response:
Immune cells such as macrophages and lymphocytes are recruited to attack abnormal cancer cells.
Tumor Cell Destruction:
Activated immune cells destroy cancer cells and prevent their regrowth.
Long-Term Protection:
Repeated treatments help maintain immune surveillance and reduce recurrence risk.
💊 Administration & Dosage
Professional Administration:
Must be administered by a trained healthcare professional in a clinical setting.
Method:
Instilled directly into the bladder through a catheter (intravesical therapy).
Typical Regimen:
Usually given once weekly for 6 weeks as induction therapy, followed by maintenance therapy if required.
Instructions for Patients:
-
The medication is retained in the bladder for approximately 2 hours.
-
Patients may be asked to change body positions during treatment for uniform exposure.
-
Fluid intake may be restricted before administration.
⚠️ Safety & Precautions
| Feature | Guideline |
|---|---|
| Infection Risk | Avoid use in patients with active urinary tract infection. |
| Immune Status | Not recommended for immunocompromised individuals. |
| Pregnancy | Should only be used if clearly prescribed by a specialist. |
| Catheter Trauma | Avoid administration if traumatic catheterization occurs. |
| Monitoring | Regular cystoscopy and medical follow-up are recommended. |
🔍 Potential Side Effects
Some side effects may occur due to immune stimulation:
Urinary Symptoms:
Burning sensation during urination, increased frequency, or mild bladder irritation.
Flu-Like Symptoms:
Fever, fatigue, chills, and body aches.
Blood in Urine:
Mild hematuria may occur temporarily.
Inflammatory Reactions:
Bladder inflammation (cystitis) or discomfort.
Rare but Serious:
Systemic BCG infection or severe immune reactions (requires immediate medical care).
📦 Storage Instructions
Temperature: Store between 2°C – 8°C (Refrigerated) unless otherwise instructed.
Protection: Protect from direct sunlight and contamination.
Handling: Reconstitute only as directed by healthcare professionals.
Safety: Keep out of reach of children.
Medical Disclaimer
Onco BCG 40 mg is a prescription immunotherapy used in the treatment of bladder cancer. The information provided here is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified oncologist or healthcare professional before starting or undergoing this therapy.
There are no reviews yet.